New York, Feb 6, 2026, 12:56 ET — Regular session
Align Technology (ALGN.O) shares climbed roughly 4% to $182.70 by midday Friday, extending gains after a strong earnings report. The stock has traded between $175.01 and $184.53 during the session.
Align Technology, the maker of Invisalign, topped Wall Street expectations late Wednesday and laid out a 2026 forecast banking on steadier demand for dental products, despite the sector’s volatility from fluctuating patient visits. Evercore ISI analyst Elizabeth Anderson noted that Align “finished off 2025 on a high note.” Reuters
This is crucial since Align’s clear-aligner “cases” — basically treatment shipments — usually see rapid drops whenever consumers and orthodontists tighten their spending. Investors want to see volume growth hold steady, along with pricing that remains firm.
Align reported fourth-quarter revenue of $1.0476 billion, with non-GAAP earnings coming in at $3.29 per share, excluding restructuring and other one-time costs. The company shipped a record 676,900 clear-aligner cases. CEO Joe Hogan highlighted “better than expected revenues and Clear Aligner volumes,” while CFO John Morici described Q4 as “a good finish to the year,” adding he remains “cautiously optimistic” despite a “dynamic” macro environment. Align also took $67.5 million in restructuring and accelerated depreciation charges during the quarter. Looking ahead, it forecast first-quarter revenue between $1.01 billion and $1.03 billion. Nasdaq
After the report, the stock jumped roughly 11% in the previous session. Still, some analysts remain cautious on its valuation. Needham’s David Saxon maintained a Hold rating, pointing to a more balanced outlook following the rally, Barron’s noted.
Stifel bumped its price target up to $210 from $200 and kept its Buy rating intact. Analyst Jonathan Block described the 2026 guidance as “prudent” and expressed a “stronger” feeling about an upward bias. StreetInsider.com
Dental stocks didn’t move alone. Envista climbed roughly 16%, while Dentsply Sirona gained around 8% by midday.
When it comes to Align, investors zero in on three key metrics: case volumes, average selling price (ASP — the average price per case), and margins. A slip in any of these can send the stock tumbling, even if quarterly revenue stays steady.
The picture isn’t straightforward. Should consumer spending drop or dental visits decline again, Align’s mid-single-digit volume goals might be tough to hit. Pricing could also become complicated if rivals ramp up promotions.
Investors are gearing up for Align’s Q1 report on April 29, 2026, hoping for more clarity on whether case growth and pricing momentum are sticking through spring.
